A case of severe interstitial cystitis associated with pembrolizumab
Immune checkpoint inhibitors have emerged as a cornerstone of management in non-small-cell lung cancer (NSCLC). They are responsible for a wide spectrum of immune-related adverse effects, which greatly differ from the adverse events of standard chemotherapy. In this report, we describe a unique case...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Elsevier
2021-12-01
|
| Ráidu: | Current Problems in Cancer: Case Reports |
| Fáttát: | |
| Liŋkkat: | http://www.sciencedirect.com/science/article/pii/S2666621921000491 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|